Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients.

Wetmore JB, Mahnken JD, Mukhopadhyay P, Hou Q, Ellerbeck EF, Rigler SK, Spertus JA, Shireman TI.

Am J Kidney Dis. 2011 Jul;58(1):73-83. doi: 10.1053/j.ajkd.2011.02.387. Epub 2011 May 31.

2.

Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.

Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL.

BMJ. 2013 Oct 24;347:f6008. doi: 10.1136/bmj.f6008. Review.

3.

Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis.

Wang B, Wang F, Zhang Y, Zhao SH, Zhao WJ, Yan SL, Wang YG.

Lancet Diabetes Endocrinol. 2015 Apr;3(4):263-74. doi: 10.1016/S2213-8587(14)70256-6. Epub 2015 Feb 6. Review. Erratum in: Lancet Diabetes Endocrinol. 2015 Apr;3(4):e3.

PMID:
25660574
4.

The ABCs of cardioprotection in dialysis patients: a systematic review.

Wetmore JB, Shireman TI.

Am J Kidney Dis. 2009 Mar;53(3):457-66. doi: 10.1053/j.ajkd.2008.07.037. Epub 2008 Nov 20. Review.

PMID:
19022545
5.

Drug therapy for hypertension in hemodialysis patients.

Hörl MP, Tepel M.

Minerva Med. 2005 Aug;96(4):277-85. Review.

PMID:
16179894
6.

Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.

Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J.

Diabetologia. 2012 Mar;55(3):566-78. doi: 10.1007/s00125-011-2398-8. Epub 2011 Dec 22. Review.

7.

Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.

Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN.

Ann Intern Med. 2008 Jan 1;148(1):16-29. Epub 2007 Nov 5. Review.

PMID:
17984484
8.

Goals of antihypertensive therapy.

McVeigh GE, Flack J, Grimm R.

Drugs. 1995 Feb;49(2):161-75. Review.

PMID:
7729325
9.

Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information.

Powers BJ, Coeytaux RR, Dolor RJ, Hasselblad V, Patel UD, Yancy WS Jr, Gray RN, Irvine RJ, Kendrick AS, Sanders GD.

J Gen Intern Med. 2012 Jun;27(6):716-29. doi: 10.1007/s11606-011-1938-8. Epub 2011 Dec 7. Review.

10.

Special considerations for antihypertensive agents in dialysis patients.

Redon J, Martinez F, Cheung AK.

Blood Purif. 2010;29(2):93-8. doi: 10.1159/000245631. Epub 2010 Jan 8. Review.

PMID:
20093810
11.

[The clinical usefulness of RAAS inhibitors in hypertensive patients].

Yamaguchi K, Sata M.

Nihon Rinsho. 2012 Sep;70(9):1571-6. Review. Japanese.

PMID:
23012805
12.
13.
14.

Antihypertensive agents for preventing diabetic kidney disease.

Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD004136. doi: 10.1002/14651858.CD004136.pub3. Review.

PMID:
23235603
15.
16.

Treating hypertension with cardioprotective therapies: the role of ACE inhibitors, ARBs, and beta-blockers.

Staffileno BA.

J Cardiovasc Nurs. 2005 Sep-Oct;20(5):354-64. Review.

PMID:
16141781
17.

Treatment of hypertension in chronic kidney disease.

Toto RD.

Semin Nephrol. 2005 Nov;25(6):435-9. Review.

PMID:
16298269
18.
19.

[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].

Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.

Presse Med. 2002 Nov 9;31(36):1714-20. Review. French.

PMID:
12467154
20.

[Role of antihypertensive drugs in the treatment of migraine].

Fehér G, Pusch G.

Orv Hetil. 2015 Feb 1;156(5):179-85. doi: 10.1556/OH.2015.30056. Review. Hungarian.

PMID:
25618859
Items per page

Supplemental Content

Write to the Help Desk